140 related articles for article (PubMed ID: 16288863)
1. Sulfamoyl-4-oxoquinoline-3-carboxamides: novel potentiators of defective DeltaF508-cystic fibrosis transmembrane conductance regulator chloride channel gating.
Suen YF; Robins L; Yang B; Verkman AS; Nantz MH; Kurth MJ
Bioorg Med Chem Lett; 2006 Feb; 16(3):537-40. PubMed ID: 16288863
[TBL] [Abstract][Full Text] [Related]
2. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating.
Pedemonte N; Sonawane ND; Taddei A; Hu J; Zegarra-Moran O; Suen YF; Robins LI; Dicus CW; Willenbring D; Nantz MH; Kurth MJ; Galietta LJ; Verkman AS
Mol Pharmacol; 2005 May; 67(5):1797-807. PubMed ID: 15722457
[TBL] [Abstract][Full Text] [Related]
3. Identification of natural coumarin compounds that rescue defective DeltaF508-CFTR chloride channel gating.
Xu LN; Na WL; Liu X; Hou SG; Lin S; Yang H; Ma TH
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):878-83. PubMed ID: 18430055
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of 4-thiophen-2'-yl-1,4-dihydropyridines as potentiators of the CFTR chloride channel.
Cateni F; Zacchigna M; Pedemonte N; Galietta LJ; Mazzei MT; Fossa P; Giampieri M; Mazzei M
Bioorg Med Chem; 2009 Dec; 17(23):7894-903. PubMed ID: 19880323
[TBL] [Abstract][Full Text] [Related]
5. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.
Phuan PW; Veit G; Tan JA; Finkbeiner WE; Lukacs GL; Verkman AS
Mol Pharmacol; 2015 Oct; 88(4):791-9. PubMed ID: 26245207
[TBL] [Abstract][Full Text] [Related]
6. Model of the cAMP activation of chloride transport by CFTR channel and the mechanism of potentiators.
Moran O
J Theor Biol; 2010 Jan; 262(1):73-9. PubMed ID: 19766125
[TBL] [Abstract][Full Text] [Related]
7. Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator.
Namkung W; Kim KH; Lee MG
Gastroenterology; 2005 Dec; 129(6):1979-90. PubMed ID: 16344066
[TBL] [Abstract][Full Text] [Related]
8. Walker mutations reveal loose relationship between catalytic and channel-gating activities of purified CFTR (cystic fibrosis transmembrane conductance regulator).
Ramjeesingh M; Li C; Garami E; Huan LJ; Galley K; Wang Y; Bear CE
Biochemistry; 1999 Feb; 38(5):1463-8. PubMed ID: 9931011
[TBL] [Abstract][Full Text] [Related]
9. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
Verkman AS; Lukacs GL; Galietta LJ
Curr Pharm Des; 2006; 12(18):2235-47. PubMed ID: 16787252
[TBL] [Abstract][Full Text] [Related]
10. Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network.
Lipecka J; Norez C; Bensalem N; Baudouin-Legros M; Planelles G; Becq F; Edelman A; Davezac N
J Pharmacol Exp Ther; 2006 May; 317(2):500-5. PubMed ID: 16424149
[TBL] [Abstract][Full Text] [Related]
11. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating.
Yang H; Shelat AA; Guy RK; Gopinath VS; Ma T; Du K; Lukacs GL; Taddei A; Folli C; Pedemonte N; Galietta LJ; Verkman AS
J Biol Chem; 2003 Sep; 278(37):35079-85. PubMed ID: 12832418
[TBL] [Abstract][Full Text] [Related]
12. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2009 Oct; 48(41):9882-90. PubMed ID: 19761259
[TBL] [Abstract][Full Text] [Related]
13. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
[TBL] [Abstract][Full Text] [Related]
14. ClC and CFTR chloride channel gating.
Foskett JK
Annu Rev Physiol; 1998; 60():689-717. PubMed ID: 9558482
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrrolo[2,3-b]pyrazines derivatives as submicromolar affinity activators of wild type, G551D, and F508del cystic fibrosis transmembrane conductance regulator chloride channels.
Noel S; Faveau C; Norez C; Rogier C; Mettey Y; Becq F
J Pharmacol Exp Ther; 2006 Oct; 319(1):349-59. PubMed ID: 16829626
[TBL] [Abstract][Full Text] [Related]
16. Positioning of extracellular loop 1 affects pore gating of the cystic fibrosis transmembrane conductance regulator.
Infield DT; Cui G; Kuang C; McCarty NA
Am J Physiol Lung Cell Mol Physiol; 2016 Mar; 310(5):L403-14. PubMed ID: 26684250
[TBL] [Abstract][Full Text] [Related]
17. Strategies to investigate the mechanism of action of CFTR modulators.
Cai Z; Scott-Ward TS; Li H; Schmidt A; Sheppard DN
J Cyst Fibros; 2004 Aug; 3 Suppl 2():141-7. PubMed ID: 15463947
[TBL] [Abstract][Full Text] [Related]
18. Dynasore inhibits removal of wild-type and DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) from the plasma membrane.
Young A; Gentzsch M; Abban CY; Jia Y; Meneses PI; Bridges RJ; Bradbury NA
Biochem J; 2009 Jul; 421(3):377-85. PubMed ID: 19442237
[TBL] [Abstract][Full Text] [Related]
19. ATPase assay of purified, reconstituted CFTR protein.
Kogan I; Ramjeesingh M; Bear CE
J Cyst Fibros; 2004 Aug; 3 Suppl 2():133-4. PubMed ID: 15463945
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.
Mills AD; Yoo C; Butler JD; Yang B; Verkman AS; Kurth MJ
Bioorg Med Chem Lett; 2010 Jan; 20(1):87-91. PubMed ID: 19954980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
